Company news

BioMarin Pharmaceutical Inc. news in 2025

BioMarin Pharmaceutical Inc.'s news releases, calls and decks from 2025, newest first.

View company

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

December 19, 2025

BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10: 30 AM GMT in London, England

November 10, 2025

FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria

October 28, 2025

BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update

October 26, 2025

BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4: 30pm ET

October 21, 2025

BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting

September 7, 2025

BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism

September 5, 2025

BioMarin to Participate in Upcoming Investor Conferences

August 26, 2025

BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS

August 3, 2025

BioMarin Announces Appointment of Ian T. Clark to Board of Directors

July 31, 2025

BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4: 30pm ET

July 21, 2025

BioMarin Announces Completion of Acquisition of Inozyme

June 30, 2025

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

June 23, 2025

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

June 20, 2025

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

May 15, 2025

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

May 11, 2025

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

April 30, 2025

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4: 30pm ET

April 16, 2025

BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria

April 1, 2025

BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

March 20, 2025

BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6: 50 AM PT / 9: 50 AM ET in Boston, MA

February 24, 2025

BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

February 23, 2025

BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

February 18, 2025

BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4: 30pm ET

February 4, 2025

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

January 12, 2025

BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9: 00 am PT / 12: 00 pm ET, in San Francisco, CA

January 5, 2025

Calls in 2025

Decks in 2025